Moxifloxacin is a fluoroquinolone antibiotic used to treat various bacterial infections. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Mechanism
- Curator reviewed
The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
- Primary indication
- For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis.Curator reviewed · 13 structured indications
- Formula / weight
- C21H24FN3O4 · 401.4314 g/mol (avg)
- First approval
- Canada, 2000 · United States, 1999
- Also known as
- Moxifloxacine
- Code names
- BAY 12-8039
- Brand names
Resolves to
FABPRXSRWADJSP-MEDUHNTESA-NSMILES[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Moxifloxacin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account